Journal Watch · JAMA · 2026
Permissive Blood Pressure Targets in Pediatric Critical Care: The PRESSURE Randomized Clinical Trial.
Receipt of kidney replacement therapy and adverse events did not differ between the groups.<h4>Conclusions and relevance</h4>Adopting a permissive MAP target resulted in no significant difference in mortality and duration of invasive ventilation at 30 days compared with usual care.<h4>Trial registration</h4>isrctn.org Identifier: ISRCTN20609635; Swiss National Clinical Trial Portal: SNCTP000006590.
TL;DR
Receipt of kidney replacement therapy and adverse events did not differ between the groups.<h4>Conclusions and relevance</h4>Adopting a permissive MAP target resulted in no significant difference in mortality and duration of invasive ventilation at 30 days compared with usual care.<h4>Trial registration</h4>isrctn.org Identifier: ISRCTN20609635; Swiss National Clinical Trial Portal: SNCTP000006590.
Key findings
- A permissive MAP target led to a 37.5% reduction in median norepinephrine-equivalent total dose compared with the usual care group.
- There was no significant difference between the groups in the primary outcome (probabilistic index, 0.52 [95% CI, 0.49-0.54]; P = .23).
- Six of the 7 secondary outcomes were similar between the groups, except median (IQR) PICU length of stay was significantly shorter in survivors in the permissive MAP target vs usual care group (159 [79-286] vs 166 [92-319] hours); probabilistic index, 0.53 [95% CI, 0.50-0.56]).
- Receipt of kidney replacement therapy and adverse events did not differ between the groups.<h4>Conclusions and relevance</h4>Adopting a permissive MAP target resulted in no significant difference in mortality and duration of invasive ventilation at 30 days compared with usual care.<h4>Trial registration</h4>isrctn.org Identifier: ISRCTN20609635; Swiss National Clinical Trial Portal: SNCTP000006590.
Numbers at a glance (from the abstract)
Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.
What they did
Patients in the control group (n = 943) received usual care with MAP target set by the attending physician.<h4>Main outcomes and measures</h4>The primary outcome was a composite of mortality and duration of invasive ventilation at 30 days. Secondary outcomes included mortality at PICU discharge, time to cessation of invasive ventilation, receipt and duration of kidney replacement therapy in PICU at 30 days, and length of PICU and hospital stay.<h4>Results</h4>Of 1900 randomized patients, 910 in the permissive MAP target group and 904 in the usual care group were included for analysis of the primary outcome. Participants had a median (IQR) age of 4 (0-10) years and 44.8% were female; baseline characteristics were similar between the groups. Median (IQR) MAP while receiving vasoactive drugs was 58 (51-63) mm Hg in the permissive MAP target group and 61 (54-67) mm Hg in the usual care group.
Full abstract (original)
Background: <h4>Importance</h4>Vasoactive drugs are often given to critically ill children to treat hypotension. However, optimal mean arterial pressure (MAP) targets are unknown.<h4>Objective</h4>To evaluate whether adopting a permissive MAP target, and thereby potentially reducing exposure to vasoactive drugs, improves outcomes in hypotensive critically ill children.<h4>Design, setting, and participants</h4>This multicenter, unblinded, pragmatic randomized clinical trial was conducted in 23 pediatric intensive care units (PICUs) in 3 countries. Critically ill children receiving invasive ventilation and vasoactive drugs for hypotension were enrolled between November 2021 and May 2026. Follow-up to the 30-day outcome was completed in June 2026.<h4>Interventions</h4>Patients randomized to the intervention (n = 957) were assigned a permissive MAP target greater than the fifth percentile for age.
What they did: Patients in the control group (n = 943) received usual care with MAP target set by the attending physician.<h4>Main outcomes and measures</h4>The primary outcome was a composite of mortality and duration of invasive ventilation at 30 days. Secondary outcomes included mortality at PICU discharge, time to cessation of invasive ventilation, receipt and duration of kidney replacement therapy in PICU at 30 days, and length of PICU and hospital stay.<h4>Results</h4>Of 1900 randomized patients, 910 in the permissive MAP target group and 904 in the usual care group were included for analysis of the primary outcome. Participants had a median (IQR) age of 4 (0-10) years and 44.8% were female; baseline characteristics were similar between the groups. Median (IQR) MAP while receiving vasoactive drugs was 58 (51-63) mm Hg in the permissive MAP target group and 61 (54-67) mm Hg in the usual care group.
Results & conclusions: A permissive MAP target led to a 37.5% reduction in median norepinephrine-equivalent total dose compared with the usual care group. There was no significant difference between the groups in the primary outcome (probabilistic index, 0.52 [95% CI, 0.49-0.54]; P = .23). Six of the 7 secondary outcomes were similar between the groups, except median (IQR) PICU length of stay was significantly shorter in survivors in the permissive MAP target vs usual care group (159 [79-286] vs 166 [92-319] hours); probabilistic index, 0.53 [95% CI, 0.50-0.56]). Receipt of kidney replacement therapy and adverse events did not differ between the groups.<h4>Conclusions and relevance</h4>Adopting a permissive MAP target resulted in no significant difference in mortality and duration of invasive ventilation at 30 days compared with usual care.<h4>Trial registration</h4>isrctn.org Identifier: ISRCTN20609635; Swiss National Clinical Trial Portal: SNCTP000006590.
Abstract © the authors / JAMA (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1001/jama.2026.19747 · PubMed 42806496.
Why it matters for pharma & biotech
- Relevant to General & Medicine teams tracking JAMA for new targets, mechanisms and biomarkers.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
Frequently asked questions
What did this JAMA study find?
Receipt of kidney replacement therapy and adverse events did not differ between the groups.<h4>Conclusions and relevance</h4>Adopting a permissive MAP target resulted in no significant difference in mortality and duration of invasive ventilation at 30 days compared with usual care.<h4>Trial registration</h4>isrctn.org Identifier: ISRCTN20609635; Swiss National Clinical Trial Portal: SNCTP000006590.
What type of study is this?
It is a randomised / controlled clinical trial, published in JAMA in 2026. Patients in the control group (n = 943) received usual care with MAP target set by the attending physician.<h4>Main outcomes and measures</h4>The primary outcome was a composite of mortality and duration of invasive ventilation at 30 days.
Where can I read the original paper?
The original is at the publisher via DOI 10.1001/jama.2026.19747. PubMed ID: 42806496. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/permissive-blood-pressure-targets-in-pediatric-critical-care-the-pressur-619747/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides